OPDP Says TV Ad is Out of Bounds with Fourth Untitled Letter of 2024
FDA Law Blog: Biosimilars
SEPTEMBER 17, 2024
The approved labeling for UBRELVY includes a warning and precaution regarding hypersensitivity reactions, with the most common adverse reactions being nausea and somnolence. on March 10, 2020.
Let's personalize your content